David A Jacobsohn
Overview
Explore the profile of David A Jacobsohn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
64
Citations
1423
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dvorak C, Long-Boyle J, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, et al.
Blood Adv
. 2024 Jul;
8(23):6003-6014.
PMID: 39042892
We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent αβ-T-cell/CD19-depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to...
2.
Cuvelier G, Ng B, Abdossamadi S, Nemecek E, Melton A, Kitko C, et al.
Blood Adv
. 2022 Oct;
7(14):3612-3623.
PMID: 36219586
The National Institutes of Health Consensus criteria for chronic graft-versus-host disease (cGVHD) diagnosis can be challenging to apply in children, making pediatric cGVHD diagnosis difficult. We aimed to identify diagnostic...
3.
Subburaj D, Ng B, Kariminia A, Abdossamadi S, Lauener M, Nemecek E, et al.
Blood
. 2021 Sep;
139(2):287-299.
PMID: 34534280
Chronic graft-versus-host disease (cGVHD) is the most common cause for non-relapse mortality postallogeneic hematopoietic stem cell transplant (HSCT). However, there are no well-defined biomarkers for cGVHD or late acute GVHD...
4.
Kharfan-Dabaja M, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al.
Transplant Cell Ther
. 2021 Jul;
27(8):642-649.
PMID: 34304802
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of...
5.
Seftel M, Chitphakdithai P, Miller J, Kobusingye H, Logan B, Linenberger M, et al.
Transplant Cell Ther
. 2021 Apr;
27(4):352.e1-352.e5.
PMID: 33836890
The incidence and risk factors for severe adverse events (SAEs) in related donors (RD) of hematopoietic cell transplants is unknown. The Related Donor Safe study is a prospective observational cohort...
6.
Schultz K, Kariminia A, Ng B, Abdossamadi S, Lauener M, Nemecek E, et al.
Blood
. 2020 Feb;
135(15):1287-1298.
PMID: 32047896
Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of Childhood Cancer study (ABLE/PBMTC1202, NCT02067832) evaluated the...
7.
Rowan C, Pike F, Cooke K, Krance R, Carpenter P, Duncan C, et al.
Blood
. 2020 Jan;
135(17):1428-1437.
PMID: 31972009
Assessment of prognostic biomarkers of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation (HCT) in the pediatric age group is lacking. To address this need, we conducted a prospective cohort...
8.
Abraham A, John T, Keller M, Cruz C, Salem B, Roesch L, et al.
Blood Adv
. 2019 Jul;
3(14):2057-2068.
PMID: 31292125
Adoptive transfer of virus-specific T cells (VSTs) has been shown to be safe and effective in stem cell transplant recipients. However, the lack of virus-experienced T cells in donor cord...
9.
Cuvelier G, Nemecek E, Wahlstrom J, Kitko C, Lewis V, Schechter T, et al.
Blood
. 2019 May;
134(3):304-316.
PMID: 31043425
Chronic graft-versus-host disease (cGVHD) and late acute graft-versus-host disease (L-aGVHD) are understudied complications of allogeneic hematopoietic stem cell transplantation in children. The National Institutes of Health Consensus Criteria (NIH-CC) were...
10.
Bolanos-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al.
Lancet Haematol
. 2019 Mar;
6(3):e132-e143.
PMID: 30824040
Background: Prevention of graft-versus-host disease (GvHD) without malignant relapse is the overall goal of allogeneic haemopoietic cell transplantation (HCT). We aimed to evaluate regimens using either maraviroc, bortezomib, or post-transplantation...